Krystal Biotech, Inc. (KRYS)

USD 156.64

(-7.34%)

Market Cap (In USD)

4.5 Billion

Revenue (In USD)

50.69 Million

Net Income (In USD)

10.93 Million

Avg. Volume

279.74 Thousand

Currency
USD
Country
Healthcare
Open
-
Prev. Close
-
Day Range
-
Year Range
107.5-219.34
PE
-
EPS
-
Beta Value
0.82
ISIN
US5011471027
CUSIP
501147102
CIK
1711279
Shares
-
Earnings Annoncement
-

Company Profile

Sector
Healthcare
Industry
Biotechnology
CEO
Mr. Krish S. Krishnan M.B.A., M.S.
Employee Count
-
Website
https://www.krystalbio.com
Ipo Date
2017-09-20
Details
Krystal Biotech, Inc., a clinical stage biotechnology company, engages in the field of redosable gene therapy to treat serious rare diseases in the United States. Its lead product candidate is beremagene geperpavec (B-VEC), which is in Phase III clinical study to treat dystrophic epidermolysis bullosa. The company is also involved in developing KB105 that is in Phase I/II clinical study for treating patients with deficient autosomal recessive congenital ichthyosis; KB301, which is in Phase I/II clinical stage for treating wrinkles and other presentations of aged or damaged skin; KB407 that is in preclinical stage for cystic fibrosis; and KB104, which is in preclinical stage for netherton syndrome. Its discovery stage product candidates include KB5xx for treating chronic skin diseases, KB3xx to treat aesthetic skin conditions, and KB3xx product. Krystal Biotech, Inc. was founded in 2015 and is headquartered in Pittsburgh, Pennsylvania.